Verapamil vs Steroid to Prevent Keloid Recurrence

Phase 4TerminatedNCT01720056

The University of Western Australia14 enrolled

Overview

Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard treatment is yet to be clarified. This randomized clinical pilot study will compare the effects of two local treatments for preventing keloid recurrence after surgical removal; steroid and verapamil. Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Keloid Scars

Interventions

VerapamilDRUG

Kenalog 10DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient undergoing surgical removal of keloid * Patient 18 years old or greater * Length of excisional scar after surgical removal of keloid between 2 and 10 cm Exclusion Criteria: * Keloid in face or hands * Pregnancy or lactation * Dementia * Any heart or pulmonary condition * Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists * Systemic corticosteroidal therapy * Intralesional steroid treatment within 2 months of surgery to remove keloid * Flap surgery * Lesions to face, hands and other cosmetically sensitive areas

Locations (1)

Royal Perth Hospital

Perth, Western Australia, Australia

Outcomes

Primary Outcomes

Keloid recurrence

Time frame: 1 year

Secondary Outcomes

Vancouver Scar Scale Score

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.